| Methods |
N=16
Randomized,
Open label,
Fup =24 weeks,
w/o d/o: reported |
| Participants |
Eligibility:‐
VL >2500 copies/ml for 6 months,
ART: 35 weeks on PI regimen
Age: median 38 years(37‐45),
Sex: 100% male
Baseline CD4 302(258‐355),
Baseline VL 4.5(4.0‐4.6), |
| Interventions |
12 wks STI |
| Outcomes |
STI arm:
CD4 decline: ‐ 128 cells/cubic mm.
VL rebound : + 0.84 log copies/ml (0.27‐1.07)
Adverse effects: Pneumocystic carinii pneumonia, peripheral neuropathy, thrombocytopenia |
| Notes |
Continued treatment during interruption associated with sustained clinical benefit |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
